Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet With Low-Dose, High Dose-Rate Brachytherapy
Author(s) -
Allison L. Goddard,
Ruth Ann Vleugels,
Nicole R. LeBoeuf,
Desmond A. O’Farrell,
Robert A. Cormack,
Jorgen L. Hansen,
Thomas S. Kupper,
Phillip M. Devlin
Publication year - 2015
Publication title -
jama dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.128
H-Index - 166
eISSN - 2168-6084
pISSN - 2168-6068
DOI - 10.1001/jamadermatol.2015.3028
Subject(s) - medicine , brachytherapy , dosing , radiation therapy , lesion , homogeneous , cutaneous lymphoma , external beam radiotherapy , target lesion , lymphoma , radiology , nuclear medicine , dermatology , surgery , mycosis fungoides , physics , thermodynamics , percutaneous coronary intervention , myocardial infarction
Cutaneous T-cell lymphoma (CTCL) of the hands and feet can be challenging to treat and cause significant disability for patients. Although CTCL is a highly radiosensitive tumor, the complex topography of acral surfaces presents challenges to achieving homogeneous superficial dosing of traditional electron beam therapy. In addition, traditional dosing may result in substantial acute cutaneous toxic effects. Recent reports demonstrate that low-dose palliative radiotherapy may be as effective as traditional regimens in CTCL. High dose-rate (HDR) brachytherapy allows for control of the depth of radiation penetration over complex curved surfaces. This study investigated the role of low-dose HDR brachytherapy for acral CTCL lesions.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom